Acorda resubmits drug application
Acorda Therapeutics Inc. of Hawthorne has resubmitted an application to market Fampridine-SR, a drug that would help people with multiple sclerosis walk.
The company received word from the U.S. Food and Drug Administration March 30 that its first application was lacking information and could not be accepted for review. Acorda shares dropped $5.09, or 20.44 percent, to close at $19.81 that day.
The company said it resubmitted the application after discussions with the FDA and believes it has made the changes in the application that the agency wanted.
Acorda shares rose $3.78, or 20.6 percent this morning and were trading at $22.12 at 9:47 a.m.